Beryl Drugs submits compliance report for quarter ended June 30

Beryl Drugs has filed reports with the Bombay Stock Exchange, including a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2025. According to a confirmation from Adroit Corporate Services, securities received for dematerialization from depository participants during the quarter were duly processed and confirmed with the depositories. Furthermore, the security certificates received for dematerialization have been mutilated and cancelled after verification, with depository names substituted in the register of members. This filing ensures compliance with SEBI listing obligations and disclosure requirements.